Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) on Thursday announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted in adolescents and adults simultaneously.

The ICONIC program, with icotrokinra (JNJ-2113) data from a subgroup analysis, came about through a partnership with Johnson & Johnson (NYSE:JNJ).

Data at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting show adolescents treated with once daily icotrokinra achieved higher rates of clear or almost clear skin at Week 16 compared to patients receiving placebo, with no new safety signals identified.

Also Read: ...

https://www.benzinga.com/25/04/44737545/johnson-johnson-protagonist-partnered-investigational-psoriasis-oral-pill-shows-75-of-adolescents-achieved-comple